Invokana Sales Figure Witness a Dip

Introduction

According to the fourth quarter 2017 sales earnings report released by J&J, Invokana made $262 million which was a 29% dip when compared to the previous reports. The low figures are reasoned to be due to the growing competition and awareness of the side-effects associated with this the Type 2 diabetes medication.

Comments

Supreme Court Upholds Flavored Vape Ban

Categories: E-Cigarette: JUUL

The U.S. Supreme Court has unanimously upheld a decision by the Food and Drug Administration (FDA) to block the sale and marketing of certain flavored e-cigarette products.

The ruling supports the FDA’s authority to regulate tobacco…

Judge Rejects JnJ's $10B Talc Lawsuit Settlement

Categories: Talcum

Johnson & Johnson's shares fell more than 5% after a U.S. bankruptcy judge rejected its $10 billion settlement proposal aimed at resolving over 60,000 lawsuits.

These lawsuits allege that the company’s…

Tepezza Hearing Loss MDL: Bellwether Trials Set for 2026

Categories: Tepezza

A U.S. District Judge overseeing Tepezza hearing damage lawsuits nationwide has scheduled four bellwether trials for 2026. These trials are intended to help both parties assess how juries may respond to the evidence and testimonies that could be…

Invokana Sales Figure Witness a Dip